ArticleFrontiers in genetics2018
DREAMSeq: An Improved Method for Analyzing Differentially Expressed Genes in RNA-seq Data.
Article in Frontiers in genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 15 citations in OpenAlex.
- Coactosin-like F-actin binding protein (Cotl1) plays a key role in adipocyte differentiation and obesity.Communications biology · 2025Article
- Differential expression analysis using a model-based gene clustering algorithm for RNA-seq data.BMC bioinformatics · 2021Article
- The regulatory genome of the malaria vectorNAR genomics and bioinformatics · 2021Article
- MoAIMS: efficient software for detection of enriched regions of MeRIP-Seq.BMC bioinformatics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA sequencing (RNA-seq) has become a widely used technology for analyzing global gene-expression changes during certain biological processes. It is generally acknowledged that RNA-seq data displays equidispersion and overdispersion characteristics; therefore, most RNA-seq analysis methods were developed based on a negative binomial model capable of capturing both equidispersed and overdispersed data. In this study, we reported that in addition to equidispersion and overdispersion, RNA-seq data also displays underdispersion characteristics that cannot be adequately captured by general RNA-seq analysis methods. Based on a double Poisson model capable of capturing all data characteristics, we developed a new RNA-seq analysis method (DREAMSeq). Comparison of DREAMSeq with five other frequently used RNA-seq analysis methods using simulated datasets showed that its performance was comparable to or exceeded that of other methods in terms of type I error rate, statistical power, receiver operating characteristics (ROC) curve, area under the ROC curve, precision-recall curve, and the ability to detect the number of differentially expressed genes, especially in situations involving underdispersion. These results were validated by quantitative real-time polymerase chain reaction using a real Foxtail dataset. Our findings demonstrated DREAMSeq as a reliable, robust, and powerful new method for RNA-seq data mining. The DREAMSeq R package is available at http://tanglab.hebtu.edu.cn/tanglab/Home/DREAMSeq.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.